Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Silence Therapeutics (SLN – Research Report) and keeping the price ...

H.C. Wainwright analyst Patrick Trucchio reiterates a Buy rating and $75 price target on Silence Therapeutics (SLN) shares following a recent ...

I am a 66-year-old white male who is active and relatively healthy. I have recently been diagnosed with prostate cancer. One ...

As you say, not all trials found a benefit, but the largest trial found that intrathecal injections — which are similar to ...

Finally, Protagonist Therapeutics (NASDAQ:PTGX) has indicated that its financial runway extends beyond the fourth quarter of 2028, providing the company with a stable foundation to continue its ...

Merit Financial Group LLC bought a new stake in shares of Incyte Co. (NASDAQ:INCY – Free Report) in the 4th quarter, ...

Disc Medicine is in strong financial shape, advancing key candidates. Find out why IRON stock could be a strong investment ...

Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities and investment strategy. | “There's an evolution of our economic model that starts with IRA, and will get worse and ...

Shares of Incyte INCY have risen 15.3% in the past twelve months against the industry’s decline of 14.3%. The stock has ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

I read your recent column on shingles. I am 66 and in fairly good health. I had both Shingrix shots about five years ago and take hydroxyurea for polycythemia vera (PV).

Perlmutter Cancer Center at NYU Langone was 1 of 3 sites to take part in the Association of Cancer Care Centers quality improvement initiative in myeloproliferative neoplasms (MPNs).